Oxford, MS 5/9/2011 (PennyPayDay) -- BrainStorm Cell Therapeutics Inc. (OTC:BCLI), a developer of adult stem cell technologies and therapeutics, announced today, in a press release, that it will open today’s trading session on the Over-the Counter Bulletin Board (“OTCBB”). As I write, shares of BCLI were up 7 percent at $0.28 per share on light volume of 37,000 shares.As previously announced, the Company has been current on all its filings and has been eligible to trade on the OTCBB. However, due to issues related to the market makers that quote on the OTCBB, the Company, together with hundreds of other companies, stopped being quoted on the OTCBB in February 2011. The issues were rectified and once again the Company’s stock will be reinstated for trading on the OTCBB.
BrainStorm’s core technology NurOwn processes adult human mesenchymal stem cells that are present in bone marrow and are capable of self-renewal as well as differentiation into many other cell types. The research team is among the first to have successfully achieved the in vitro differentiation of adult bone marrow cells (animal and human) into astrocyte-like cells capable of releasing neurotrophic factors, including glial-derived neurotrophic factor (GDNF).
The ability to induce differentiation into astrocyte-like cells along with intramuscular or intrathecal (or other) delivery makes NurOwn technology highly attractive for treating ALS and Parkinson’s disease as well as MS and spinal cord injury.
BrainStorm’s stem cell therapy contains human mesenchymal stromal cells induced to differentiate into astrocyte-like cells secreting neurotrophic factors by means of a specific differentiation-inducing culture medium.
BrainStorm Cell Therapeutics Inc. is a company developing adult stem cell therapeutic products, derived from autologous (self) bone marrow cells, for the treatment of neurodegenerative diseases.
For more information, visit the company’s website at www.brainstorm-cell.com.
No comments:
Post a Comment